Page 1

TW TWIST BIOSCIENCE Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results August 6 , 2021 -- Revenue Growth of 65 % over Fiscal 2020 Third Quarter -- -- Order Growth of 58 % Year over Year -- -- Gross Margin of 40 % for the Quarter -- SOUTH SAN FRANCISCO , Calif .-- ( BUSINESS WIRE ) -- Aug . 6 , 2021-- Twist Bioscience Corporation ( NASDAQ : TWST ) , a company enabling customers to succeed through its offering of high - quality synthetic DNA using its silicon platform , today reported financial results and business highlights for the third quarter of fiscal 2021 ended June 30 , 2021 . " It is an exciting time to be at the forefront of synthetic biology , " said Emily M. Leproust , Ph.D. , CEO and co - founder of Twist Bioscience . " The opportunity continues to expand as our customers pursue new and innovative solutions to life's grand challenges in the areas of healthcare , sustainable chemicals , food , agriculture and more . Together with the promise of future applications , we continue to deliver solid revenue growth and extend our proprietary silicon - based DNA synthesis platform to new markets ripe for disruption . " FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS • Orders : Total orders received for the third quarter of fiscal 2021 were $ 39.1 million , compared to $ 24.7 million for the same period of fiscal 2020 . • Revenue : Total revenues were $ 35.0 million for the third quarter of fiscal 2021 compared to $ 21.2 million for the same period of fiscal 2020 . • Cost of Revenues : Cost of revenues for the third quarter of fiscal 2021 was $ 20.9 million compared to $ 16.5 million for the same period of fiscal 2020 . • Research and Development Expenses : Research and development expenses for the third quarter of fiscal 2021 were $ 19.8 million compared to $ 10.4 million for the same period of fiscal 2020 . • Selling , General and Administrative Expenses : Selling , general and administrative expenses for the third quarter of fiscal 2021 were $ 34.5 million compared to $ 22.5 million for the same period of fiscal 2020 . • Net Loss : Net loss for the third quarter of fiscal 2021 was $ 40.0 million , or $ 0.82 per share , compared to $ 28.2 million , or $ 0.67 per share , for the third quarter of fiscal 2020 . • Cash Position : As of June 30 , 2021 , the company had $ 519.4 million in cash , cash equivalents and short - term investments . " Our gross margin was 40 % for the quarter , reflecting the higher contribution margin and mix of NGS tools . We are raising our revenue guidance based on continued strength across our business , " commented Jim Thorburn , CFO of Twist . Fiscal Third Quarter 2021 and Recent Highlights • Shipped products to approximately 1,800 customers in the third quarter of fiscal 2021 versus approximately 1,400 in the same period of fiscal 2020 . • Shipped 107,000 genes during the third quarter versus 83,000 in the same period of fiscal 2020 . • Supported the Engineering Biology Research Consortium ( EBRC ) and its Statement of Ethics in Engineering Biology Research . A companion paper , titled " Guiding ethical principles in engineering biology research , " to contextualize the purpose and principles behind the Statement has also now been published in ACS Synthetic Biology . • Acquired iGenomX , a company offering multiplex library preparation tools for next - generation sequencing ( NGS ) workflows . The acquisition is expected to enhance Twist's capabilities to support multiplex sequencing preparations across multiple markets and to accelerate Twist's conversion of customers from static microarray platforms to genotyping by sequencing workflows . • Launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0 , a robust all - in - one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next - generation sequencing ( NGS ) . The kit is optimized for challenging NGS applications including liquid biopsy , somatic variant testing and genome - wide association studies . In addition , the kit excels in preparing samples where the amount of sample input DNA is either very limited or heavily degraded , as in the case of many banked oncology samples . • Announced a collaboration with Regeneron Genetics Center LLC ( RGC ) , a wholly - owned subsidiary of Regeneron , for the